Vaccine Response Tracking for Healthy Adults

(WU 445 Trial)

This trial aims to determine how the immune system responds to and remembers different vaccines by administering four FDA-approved vaccines simultaneously. The vaccines include the yearly flu shot (trivalent inactivated influenza vaccine, TIV), a booster for tetanus and whooping cough (tetanus, diphtheria, and acellular pertussis vaccine, Tdap), an HPV vaccine (nonavalent HPV vaccine), and a hepatitis A vaccine (hepatitis A, HAV, vaccines). Ideal participants are healthy adults who have not recently received these vaccines and are willing to provide blood and bone marrow samples. The study spans 24 months, with several follow-up visits to monitor health and immune response. As a Phase 4 trial, this research focuses on understanding how these already FDA-approved and effective vaccines benefit more patients.

The trial does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive drugs or have received certain vaccines recently, you may not be eligible to participate.

Past research has shown that hepatitis A vaccines have been administered to millions without causing serious side effects. A safety review using the Vaccine Adverse Event Reporting System (VAERS) found no safety concerns. For the nonavalent HPV vaccine, over 135 million doses have been administered in the U.S., providing strong safety evidence. Serious health issues after HPV vaccination are very rare, occurring in only about 1.8 cases per 100,000 doses.

The tetanus, diphtheria, and acellular pertussis (Tdap) vaccine is also safe and has been recommended since 2006 for teenagers and adults. The flu vaccine (trivalent inactivated influenza vaccine or TIV) has a long history of safety, having been used in the U.S. for many years without major safety concerns.

Researchers are excited about this trial because it explores a unique approach to vaccine administration by giving four different vaccines simultaneously. This method could streamline the vaccination process, making it more efficient for healthy adults to receive important immunizations against diseases like influenza, tetanus, diphtheria, pertussis, HPV, and hepatitis A in one visit. By tracking the immune response to these vaccines when given together, researchers hope to gather valuable data that could simplify vaccination schedules and improve overall public health strategies.

Research has shown that the hepatitis A (HAV) vaccine is highly effective, with studies indicating that up to 97% of people develop protective antibodies after completing the vaccination series. Evidence supports the nonavalent HPV vaccine's high effectiveness in preventing HPV infections, with success rates ranging from 53.9% to 100% depending on the dosage. The Tdap vaccine generates strong immune responses against tetanus, diphtheria, and pertussis (whooping cough), providing solid protection soon after vaccination. The trivalent inactivated influenza vaccine (TIV) has demonstrated varied effectiveness, from 24% to 71%, in preventing the flu, especially across different age groups and seasons. In this trial, participants will receive all four vaccines—HAV, HPV, Tdap, and TIV—administered intramuscularly at a single visit. All these vaccines have FDA approval and have proven safe and effective in protecting against their respective diseases.⁶⁷⁸⁹¹⁰